LOGIN  |  REGISTER
Recursion
Compass Therapeutics

R1 RCM to Present at Upcoming Investor Conferences

February 16, 2024 | Last Trade: US$14.31 0.00 0.00

MURRAY, Utah, Feb. 16, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

  • The 2024 TD Cowen Healthcare Conference on Monday, March 4 at 10:30am ET
  • The 2024 Barclays Global Healthcare Conference on Wednesday, March 13 at 4:35pm ET

A live audio webcast of each presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contacts

Investor Relations:
Evan Smith, CFA
(516) 743-5184
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact: 
Yancey Casey
Amendola Communications
(678) 895-9401
This email address is being protected from spambots. You need JavaScript enabled to view it.


Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB